How big is Novo Integrated Sciences, Inc.?

As of Jun 18, Novo Integrated Sciences, Inc. has a market capitalization of 0.07 million, categorizing it as a Micro Cap company, with net sales of 13.29 million and a net profit of -16.14 million over the latest four quarters. As of August 2024, the company's shareholder's funds were 14.89 million, and total assets were 32.14 million.

Market Cap: As of Jun 18, Novo Integrated Sciences, Inc. has a market capitalization of 0.07 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 13.29 million and a net profit of -16.14 million.<BR><BR>Balance Sheet Snapshot: As of August 2024, the company's shareholder's funds amounted to 14.89 million, while total assets were reported at 32.14 million.

What does Novo Integrated Sciences, Inc. do?

Novo Integrated Sciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $3 million and a net profit of $5 million as of August 2024. The company has a market cap of $0.07 million and shows a return on equity of -120.60%.

Overview: <BR>Novo Integrated Sciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Million (Quarterly Results - Aug 2024) <BR>Most recent Net Profit: 5 Million (Quarterly Results - Aug 2024) <BR>Market-cap: USD 0.07 Million <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.25 <BR>Return on Equity: -120.60% <BR>Price to Book: 0.00 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Novo Integrated Sciences, Inc.?

Is Novo Integrated Sciences, Inc. overvalued or undervalued?

As of November 6, 2024, Novo Integrated Sciences, Inc. is deemed overvalued and classified as "does not qualify" due to poor financial health, reflected in its negative valuation metrics and a year-to-date return of -99.04%, significantly underperforming compared to the S&P 500's 12.22% gain.

As of 6 November 2024, the valuation grade for Novo Integrated Sciences, Inc. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company appears to be overvalued given its current valuation metrics, which include a Price to Book Value of 0.01, an EV to EBIT of -0.46, and an EV to EBITDA of -0.63. These ratios suggest that the company is not generating positive earnings or cash flows, which is critical for valuation.<BR><BR>In comparison to its peers, Novo Integrated Sciences shows a stark contrast; for instance, Sera Prognostics, Inc. has an EV to EBITDA of -2.2464, while IMAC Holdings, Inc. stands at -0.2777. This highlights that even among similarly struggling companies, Novo Integrated Sciences is lagging significantly. Additionally, the stock has experienced a drastic decline, with a year-to-date return of -99.04% compared to a 12.22% gain in the S&P 500, reinforcing the notion that the company is not only overvalued but also facing severe operational challenges.

Is Novo Integrated Sciences, Inc. technically bullish or bearish?

As of August 25, 2025, Novo Integrated Sciences, Inc. is in a mildly bearish trend, with key indicators showing overall bearish signals despite some mildly bullish weekly metrics, and the stock has underperformed significantly with a -99.82% return over the past year compared to the S&P 500's 17.14% return.

As of 25 August 2025, the technical trend for Novo Integrated Sciences, Inc. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators such as the daily moving averages indicating a mildly bearish position, while the monthly KST is bearish. Although the weekly MACD and OBV are mildly bullish, they are overshadowed by the overall bearish signals from the monthly Dow Theory and the daily moving averages. Over the past year, the stock has returned -99.82%, significantly underperforming the S&P 500, which returned 17.14%.